Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...
It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...
The Chosun Ilbo on MSN
Oral obesity drugs near FDA approval, domestic launch planned
New obesity treatments such as 'oral Mounjaro' and 'high-dose Wegovy' are scheduled to be released next year. The U.S. Food ...
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
The White House is set to announce drug pricing deals with pharmaceutical giants Novartis and Roche Holding as soon as Friday, Bloomberg News reported on Wednesday, citing people familiar with the ...
Eli Lilly and Company has delivered significant positive developments this week, though its shares experienced a minor pullback in Wednesday's trading sessio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback